Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 199Leukemia, Lymphocytic, Chronic, B-Cell 169Leukemia 165Myelodysplastic Syndromes 162Precursor Cell Lymphoblastic Leukemia-Lymphoma 151Lymphoma, Non-Hodgkin 129Lymphoma 120Multiple Myeloma 112Hodgkin Disease 110Lymphoma, Follicular 97Lymphoma, Mantle-Cell 95Lymphoma, Large B-Cell, Diffuse 87Lymphoma, B-Cell, Marginal Zone 79Myeloproliferative Disorders 77Burkitt Lymphoma 75Congenital Abnormalities 73Leukemia, Myelogenous, Chronic, BCR-ABL Positive 67Leukemia, Myelomonocytic, Chronic 66Leukemia, Myeloid, Chronic-Phase 64Leukemia, Myeloid, Accelerated Phase 62Recurrence 57Lymphoma, Large-Cell, Immunoblastic 55Waldenstrom Macroglobulinemia 50Anemia, Refractory, with Excess of Blasts 50Primary Myelofibrosis 48Neoplasms, Plasma Cell 47Blast Crisis 47Hematologic Neoplasms 40Leukemia, Prolymphocytic 37Dendritic Cell Sarcoma, Interdigitating 37

Interventions

fludarabine phosphate 1fludarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Mesothelin-positive Advanced Refractory Solid Tumors × fludarabine phosphate × Clear all
NCT05531708 2023-03-01

Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors

Shanghai Pudong Hospital

Phase 1 Withdrawn
Other solid neoplasm

Mesothelin-positive Advanced Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡